<DOC>
	<DOCNO>NCT02448641</DOCNO>
	<brief_summary>Controlled study stereotactic , intracranial injection SB623 cell patient fixed motor deficit ischemic stroke</brief_summary>
	<brief_title>Study Modified Stem Cells ( SB623 ) Patients With Chronic Motor Deficit From Ischemic Stroke</brief_title>
	<detailed_description>This double-blind , sham-surgery control study stereotactic , intracranial injection SB623 cell patient fixed motor deficit ischemic stroke . The study conduct approximately 65 site United States . Two cohort , Group 1 ( 2.5 5 million SB623 cell combine ) Group 2 ( sham placebo ) , include study . Subjects randomize study receive either 2.5 million SB623 cell , 5 million SB623 cell sham surgery 1:1:1 randomization ratio . Randomization perform via interactive web/voice response system ( IXRS ) , stratify Screening mRS score ( record IXRS clinical site ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . Age 1875 year , inclusive 2 . Documented history complete ischemic stroke subcortical region MCA lenticulostriate artery without cortical involvement , correlate finding MRI 3 . Between 6 90 month ( 7.5 year ) poststroke , chronic motor neurological deficit 4 . Neurological motor deficit substantially due incident stroke 5 . Modified Rankin Score 24 6 . Require Motricity Index 3075 ( UE Scale ) 2774 ( LE Scale ) 7 . Able undergo plan neurological assessment 8 . Able willing undergo magneti resonance imaging ( MRI ) contrast compute tomography ( CT ) 9 . Agree use antiplatelet , anticoagulant , nonsteroidal antiinflammatory drug determine local medical staff accordance ACCP 2012 guideline `` Perioperative Management Antithrombotic Therapy : Antithrombotic Therapy Prevention Thrombosis , 9th Edition : American College Chest Physicians EvidenceBased Clinical Practice Guidelines '' , applicable , provided antiplatelet , anticoagulant , nonsteroidal antiinflammatory drug restart postsurgery Day 8 MRI read determine safe restart 10 . Subjects must physical therapy prior entry ( willing continue extent possible ) 11 . Must willing discontinue herbal nontraditional medicine 1 week 1 week surgical procedure willing continue extent possible 12 . Ability patient legal authorize representative understand sign Informed Consent 1 . History presence major neurological disease stroke 2 . Cerebral infarct size &gt; 150 cm3 measure MRI 3 . Primary intracerebral hemorrhage 4 . Myocardial infarction within prior 6 mo . 5 . Malignancy unless remission &gt; 5 yr . 6 . Clinically significant find MRI brain relate stroke 7 . Any seizure 3 month prior Screening 8 . More 5 degree contracture shoulder , elbow , wrist , finger , hip , knee ankle 9 . Other neurologic , neuromuscular orthopedic disease limit motor function 10 . Uncontrolled systemic illness , include , limited : hypertension ; diabetes ; renal , hepatic , cardiac failure 11 . Positive finding test occult malignancy , unless nonmalignant etiology confirm 12 . Uncontrolled major psychiatric illness , include depression symptom ( CESD R Scale ≥16 exclusionary ) 13 . Total bilirubin &gt; 1.9 mg/dL Screening 14 . Serum creatinine &gt; 1.5 mg/dL Screening 15 . Hemoglobin &lt; 10.0 g/dL Screening 16 . Absolute neutrophil count &lt; 2000 /mm3 Screening 17 . Absolute lymphocytes &lt; 800 /mm3 Screening 18 . Platelet count &lt; 100,000 /mm3 Screening 19 . Liver disease support AST ( SGOT ) ALT ( SGPT ) ≥2.5 x upper limit normal Screening 20 . Serum calcium &gt; 11.5 mg/dL Screening 21. International Normalized Ratio Prothrombin Time ( INR ) &gt; 1.2 Screening patient take anticoagulant ; patient anticoagulant , INR must confirm ≤1.2 prior surgery 22 . Presence craniectomy contraindication stereotactic surgery 23 . Participation investigational trial within 4 week initial screen within 7 week Baseline visit 24 . Botulinum toxin injection , phenol injection , intrathecal baclofen , interventional treatment spasticity ( except brace splint ) 16 week prior Baseline visit 25 . Substance use disorder ( per DSMV criterion , include drug alcohol ) 26 . Contraindications head MRI ( constrast ) CT 27 . Pregnant lactate 28 . Female patient childbearing potential unwilling use adequate birth control method 12 month study 29 . Any condition situation investigator believe may interfere safety subject intent conduct study 30 . Any prior SB623 cell implantation and/or prior stem cell treatment stroke reason regardless mode administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>chronic stroke</keyword>
	<keyword>fix motor deficit</keyword>
</DOC>